Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

John W. Smith, Marc E. Buyse, Priya Rastogi, Charles E. Geyer, Samuel A. Jacobs, Erica J. Patocskai, André Robidoux, Alison K. Conlin, Bilal Ansari, George P. Keogh, Philip J. Stella, Howard M. Gross, Raymond S. Lord, Jonathan A. Polikoff, Celine Mauquoi, Eleftherios P. Mamounas, Sandra M. Swain, Norman Wolmark

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5'. Together they form a unique fingerprint.

Medicine & Life Sciences